Tumor size and surgical margins are important prognostic factors of synovial sarcoma - A retrospective study.
Chemotherapy
Orthopedic oncology
Radiotherapy
Soft tissue sarcoma
Synovial sarcoma
Journal
Journal of orthopaedics
ISSN: 0972-978X
Titre abrégé: J Orthop
Pays: India
ID NLM: 101233220
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
10
04
2023
revised:
28
06
2023
accepted:
06
07
2023
pmc-release:
01
08
2024
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Synovial Sarcoma (SS) is a rare soft tissue sarcoma. Mean time to get a SS diagnosis from the onset of symptoms is 10 years, furthermore, SS is associated with late metastasis. Surgery is the main treatment option, whose quality deeply affects SS outcomes, and it can be associated to preoperative or post-operative radiotherapy. Chemotherapy is considered very effective in Children, while in adults its efficacy is still under debate. The aim of this study was to investigate the oncologic results in SS treatment and to identify the risk factors for local and systemic control of the disease. From 1994 to 2018, 211 patients affected by SS were treated in 3 Referral Centres of Orthopaedic Oncology. One hundred seventy-seven patients were included in the study, the median follow-up length was 96 months (5-374). Overall Survival on the Kaplan Meier Analyses was 80%, 70% and 56% at 5, 10 and 20 years. In multivariate analyses, OS correlated with tumour size and negative surgical margins. Chemotherapy use wasn't associated with better survival although patients who underwent CT had bigger and more aggressive tumours. Our findings suggests that surgery with negative margins is the most important factor in Synovial Sarcoma. Adjuvant treatments as chemotherapy and radiation therapy didn't change the disease's course.
Sections du résumé
Background
UNASSIGNED
Synovial Sarcoma (SS) is a rare soft tissue sarcoma. Mean time to get a SS diagnosis from the onset of symptoms is 10 years, furthermore, SS is associated with late metastasis. Surgery is the main treatment option, whose quality deeply affects SS outcomes, and it can be associated to preoperative or post-operative radiotherapy. Chemotherapy is considered very effective in Children, while in adults its efficacy is still under debate. The aim of this study was to investigate the oncologic results in SS treatment and to identify the risk factors for local and systemic control of the disease.
Methods
UNASSIGNED
From 1994 to 2018, 211 patients affected by SS were treated in 3 Referral Centres of Orthopaedic Oncology. One hundred seventy-seven patients were included in the study, the median follow-up length was 96 months (5-374).
Results
UNASSIGNED
Overall Survival on the Kaplan Meier Analyses was 80%, 70% and 56% at 5, 10 and 20 years. In multivariate analyses, OS correlated with tumour size and negative surgical margins. Chemotherapy use wasn't associated with better survival although patients who underwent CT had bigger and more aggressive tumours.
Conclusions
UNASSIGNED
Our findings suggests that surgery with negative margins is the most important factor in Synovial Sarcoma. Adjuvant treatments as chemotherapy and radiation therapy didn't change the disease's course.
Identifiants
pubmed: 37533628
doi: 10.1016/j.jor.2023.07.002
pii: S0972-978X(23)00149-6
pmc: PMC10391603
doi:
Types de publication
Journal Article
Langues
eng
Pagination
74-79Informations de copyright
© 2023 Published by Elsevier B.V. on behalf of Professor P K Surendran Memorial Education Foundation.
Déclaration de conflit d'intérêts
Each author certifies that he or she has no commercial associations(eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc that might pose a conflict of interest in connection with the submitted article.
Références
J Clin Oncol. 2003 Apr 15;21(8):1602-11
pubmed: 12697886
Oncogene. 2016 Jul 28;35(30):3932-43
pubmed: 26640147
Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27
pubmed: 12829150
Biomark Res. 2017 Feb 7;5:4
pubmed: 28191313
J Clin Oncol. 1987 Apr;5(4):601-12
pubmed: 3559651
Clin Cancer Res. 2008 Dec 15;14(24):8191-7
pubmed: 19088035
Cancer. 1986 Jul 1;58(1):190-205
pubmed: 3518911
J Clin Oncol. 2004 Oct 15;22(20):4040-50
pubmed: 15364967
Am J Clin Oncol. 2004 Apr;27(2):113-21
pubmed: 15057148
Lancet. 1997 Dec 6;350(9092):1647-54
pubmed: 9400508
J Clin Oncol. 2000 May;18(10):2087-94
pubmed: 10811674
Pediatr Blood Cancer. 2006 Jan;46(1):11-7
pubmed: 16292743
J Clin Oncol. 2003 Jul 15;21(14):2719-25
pubmed: 12860950
Cancer. 2008 Aug 1;113(3):573-81
pubmed: 18521899
J Clin Oncol. 1996 May;14(5):1679-89
pubmed: 8622088
J Clin Oncol. 1997 Feb;15(2):646-52
pubmed: 9053489
Cancer. 2009 Jul 1;115(13):2988-98
pubmed: 19452538
Eur J Cancer. 2016 May;58:62-72
pubmed: 26968015
Sarcoma. 2011;2011:231789
pubmed: 21559258
Ann Diagn Pathol. 2014 Dec;18(6):369-80
pubmed: 25438927
Ann Oncol. 2011 Feb;22(2):458-67
pubmed: 20716627
Ann Surg Oncol. 2016 Dec;23(Suppl 5):618-626
pubmed: 27638676
J Surg Oncol. 2012 Aug 1;106(2):162-8
pubmed: 22297839
Am J Clin Oncol. 2013 Feb;36(1):83-8
pubmed: 22270107
J Am Coll Surg. 2001 Mar;192(3):305-13
pubmed: 11245372
Lancet Oncol. 2012 Oct;13(10):1045-54
pubmed: 22954508
Eur J Surg Oncol. 2017 Sep;43(9):1733-1739
pubmed: 28579008
Ann Oncol. 2009 Mar;20(3):425-30
pubmed: 19088169
Clin Orthop Relat Res. 2010 Nov;468(11):3012-8
pubmed: 20700676
Clin Orthop Relat Res. 2004 Feb;(419):155-61
pubmed: 15021147
Cancer. 1981 Mar 1;47(5):1005-22
pubmed: 7226034
Cancer. 1991 Apr 15;67(8):2083-6
pubmed: 2004326
Eur J Cancer. 2000 Apr;36(6):710-6
pubmed: 10762742
J Cancer. 2017 Jul 1;8(10):1759-1768
pubmed: 28819372
Ann Surg Oncol. 1996 May;3(3):255-60
pubmed: 8726180
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1460-9
pubmed: 17394945
Musculoskelet Surg. 2017 Dec;101(3):243-248
pubmed: 28444540
Ann Surg Oncol. 2001 Jul;8(6):509-18
pubmed: 11456050
Ann Surg Oncol. 1997 Jan;4(1):1-12
pubmed: 8985511
Ann Diagn Pathol. 1998 Dec;2(6):401-21
pubmed: 9930576
Cancer Med. 2014 Oct;3(5):1404-15
pubmed: 25044961
Am J Clin Oncol. 2017 Jun;40(3):306-311
pubmed: 25350464
Cancer. 1999 Jan 15;85(2):389-95
pubmed: 10023707
Clin Sarcoma Res. 2016 Oct 14;6:18
pubmed: 27777717
Int J Clin Oncol. 2003 Apr;8(2):104-9
pubmed: 12720103
Ann Surg Oncol. 2007 May;14(5):1583-90
pubmed: 17260106
J Surg Oncol. 2017 Sep;116(4):550-558
pubmed: 28580620
J Surg Oncol. 2016 Sep;114(4):490-4
pubmed: 27220538
J Clin Oncol. 2001 Mar 1;19(5):1238-47
pubmed: 11230464
J Bone Joint Surg Br. 1993 Jul;75(4):658-60
pubmed: 8331127
Ann Oncol. 2015 Mar;26(3):567-72
pubmed: 25488687
Semin Radiat Oncol. 1999 Oct;9(4):369-77
pubmed: 10516384
Cancer. 1990 Mar 1;65(5):1119-29
pubmed: 2302663
J Clin Oncol. 2001 Jan 15;19(2):525-34
pubmed: 11208847
J Clin Oncol. 2005 Jan 1;23(1):96-104
pubmed: 15625364
Clin Orthop Relat Res. 2010 Nov;468(11):3003-11
pubmed: 20645035
J Clin Epidemiol. 1989;42(2):105-10
pubmed: 2918320
Oncology. 2003;65 Suppl 2:80-4
pubmed: 14586155
Cancers (Basel). 2018 Nov 01;10(11):
pubmed: 30388821
Cancer. 2004 Aug 1;101(3):627-34
pubmed: 15274077
Cancer. 2009 Aug 1;115(15):3537-47
pubmed: 19514087
J Clin Oncol. 1996 Apr;14(4):1201-8
pubmed: 8648375
Clin Orthop Relat Res. 2018 Sep;476(9):1791-1800
pubmed: 30794216
J Bone Joint Surg Br. 1997 Jul;79(4):553-7
pubmed: 9250737
Oncol Lett. 2018 Feb;15(2):2179-2187
pubmed: 29434923
Clin Orthop Relat Res. 2008 Sep;466(9):2156-67
pubmed: 18563504
Br J Cancer. 2014 Mar 18;110(6):1456-64
pubmed: 24481401